Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

Clinical trial NCT07365410 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07365410
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer (NSCLC)Brain Metastases Furmonertinib EGFR Mutation

Start date: 2026-01-01
Primary completion: 2026-05-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.